1492 Capital Management LLC Invests $847,000 in Astrana Health, Inc. (NASDAQ:ASTH)

1492 Capital Management LLC acquired a new position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 26,857 shares of the company's stock, valued at approximately $847,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Astrana Health during the 4th quarter worth about $40,000. KBC Group NV lifted its stake in Astrana Health by 108.4% in the 4th quarter. KBC Group NV now owns 2,530 shares of the company's stock worth $80,000 after purchasing an additional 1,316 shares in the last quarter. US Bancorp DE grew its holdings in Astrana Health by 3,880.0% in the 4th quarter. US Bancorp DE now owns 4,776 shares of the company's stock valued at $151,000 after buying an additional 4,656 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in Astrana Health by 21.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company's stock worth $223,000 after purchasing an additional 1,273 shares during the period. Finally, Envestnet Asset Management Inc. raised its position in Astrana Health by 19.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,124 shares of the company's stock valued at $225,000 after purchasing an additional 1,184 shares during the period. 52.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ASTH. Truist Financial reduced their price objective on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Stifel Nicolaus lowered their price target on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Barclays initiated coverage on Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price objective for the company. Bank of America dropped their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Finally, Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Price Performance

ASTH traded up $0.77 during midday trading on Wednesday, reaching $31.16. 50,006 shares of the company's stock were exchanged, compared to its average volume of 274,566. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $1.56 billion, a PE ratio of 23.97, a P/E/G ratio of 1.37 and a beta of 1.04. The business's 50-day moving average price is $31.66 and its 200 day moving average price is $38.76. Astrana Health, Inc. has a 1-year low of $23.12 and a 1-year high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. As a group, equities analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.